Instil Bio, Inc. Stock Price, News & Analysis

Instil Bio (Nasdaq: TIL) has received FDA clearance for its DELTA-1 Phase 2 clinical trial of ITIL-168, aimed at treating patients with advanced melanoma. The trial will focus on patients who have relapsed after PD-1 inhibitors and will include expanded cohorts for those who faced toxicity or had unsatisfactory responses. Topline results are expected in 2023, with potential regulatory submissions for a biologics license application in the U.S. and a marketing authorization in Europe in 2024.

Instil Bio, Inc. (NASDAQ: TIL) announced its participation in two investor conferences this September. The first is the Morgan Stanley 19th Annual Global Healthcare Conference on September 9 at 2:00 p.m. ET, featuring a fireside chat. Following that, Instil will present at Baird’s 2021 Virtual Global Healthcare Conference on September 14 at 5:30 p.m. ET. Live webcasts of these events will be available on the company’s website, with archived recordings accessible after the events.

Instil Bio (NASDAQ: TIL) reported significant clinical advancements in its second quarter 2021 update. In a compassionate use study for advanced melanoma, 67% of patients showed an objective response, with 19% achieving a complete response. The lead asset, ITIL-168, received orphan drug designation from the FDA. Instil is on track to initiate a Phase 2 trial for ITIL-168 in H2 2021 and a Phase 1 trial for ITIL-306 in H1 2022. Financially, cash reserves increased to $566.7 million, supporting operations through 2023.

Instil Bio (Nasdaq: TIL) announced its management will present an overview at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 9:30 a.m. ET. Interested parties can access a live webcast at here. Instil is focused on developing TIL therapies, advancing products like ITIL-168 and ITIL-306 for cancer treatment, particularly advanced melanoma and solid tumors.

Instil Bio (NASDAQ: TIL) reported its Q1 2021 financial results, highlighting a strong IPO with $368 million gross proceeds completed in March 2021. The company is advancing its lead product, ITIL-168, which received orphan drug designation from the U.S. FDA for melanoma. As of March 31, 2021, cash and equivalents reached $609.6 million, allowing operations to be funded into 2023. R&D expenses significantly increased to $14.4 million from $2 million in Q1 2020. The company plans to initiate a Phase 2 trial for ITIL-168 in advanced melanoma in H2 2021.

Instil Bio (Nasdaq: TIL) has received orphan drug designation from the FDA for its ITIL-168 therapy, targeting melanoma stages IIB to IV. This designation provides incentives such as tax credits and market exclusivity for up to seven years upon approval. ITIL-168, an autologous cell therapy utilizing tumor infiltrating lymphocytes, aims to enhance treatment efficacy with a flexible manufacturing process. Instil plans to initiate a global phase 2 trial for advanced melanoma in 2021, with further trials for other solid tumors to follow in 2022.

Instil Bio (Nasdaq: TIL) presented encouraging clinical data for its tumor infiltrating lymphocyte therapy, ITIL-168, at the AACR meeting. In a compassionate use program involving 21 metastatic melanoma patients, 67% achieved an objective response, with 19% achieving complete response. Notably, all complete responders remained in remission at data cut-off, with remissions lasting from 30 to 80 months. The company plans to initiate a Phase 2 trial for ITIL-168 in advanced melanoma later this year, aiming for FDA and EMA submissions in 2023 and 2024, respectively.

Instil Bio, Inc. has successfully closed its initial public offering, issuing 18,400,000 shares of common stock at $20.00 per share, securing approximately $368.0 million in gross proceeds. This includes the underwriters’ full exercise of their option to purchase an additional 2,400,000 shares. The offering highlights Instil's commitment to advancing its cell therapy pipeline targeting cancer treatment. The shares are traded on the Nasdaq Global Select Market under the symbol TIL, with Morgan Stanley, Jefferies, and Cowen serving as joint book-running managers.

Instil Bio has priced its initial public offering (IPO) of 16,000,000 shares at $20.00 each, aiming to raise $320 million before fees. The shares will trade on Nasdaq under the symbol TIL, starting March 19, 2021, with the offering closing on March 23, 2021, subject to customary conditions. The underwriters hold an option for an additional 2,400,000 shares. The IPO is led by Morgan Stanley, Jefferies, and Cowen, with a prospectus available through these firms. Forward-looking statements caution potential investors about inherent uncertainties.